Novo Nordisk A/S (NVO) - Total Assets
Based on the latest financial reports, Novo Nordisk A/S (NVO) holds total assets worth $542.90 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Novo Nordisk A/S - Total Assets Trend (1985–2025)
This chart illustrates how Novo Nordisk A/S's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Novo Nordisk A/S - Asset Composition Analysis
Current Asset Composition (December 2025)
Novo Nordisk A/S's total assets of $542.90 Billion consist of 31.8% current assets and 68.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.9% |
| Accounts Receivable | $75.70 Billion | 13.9% |
| Inventory | $49.62 Billion | 9.1% |
| Property, Plant & Equipment | $208.38 Billion | 38.4% |
| Intangible Assets | $110.21 Billion | 20.3% |
| Goodwill | $19.84 Billion | 3.7% |
Asset Composition Trend (1985–2025)
This chart illustrates how Novo Nordisk A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novo Nordisk A/S's current assets represent 31.8% of total assets in 2025, a decrease from 58.3% in 1985.
- Cash Position: Cash and equivalents constituted 4.9% of total assets in 2025, down from 28.6% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is property, plant & equipment at 38.4% of total assets.
Novo Nordisk A/S Competitors by Total Assets
Key competitors of Novo Nordisk A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF115.49 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
Novo Nordisk A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.80 | 0.74 | 0.85 |
| Quick Ratio | 0.57 | 0.55 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-43.21 Billion | $-56.63 Billion | $-1.74 Billion |
Novo Nordisk A/S - Advanced Valuation Insights
This section examines the relationship between Novo Nordisk A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.90 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 16.6% |
| Total Assets | $542.90 Billion |
| Market Capitalization | $136.50 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Novo Nordisk A/S's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Novo Nordisk A/S's assets grew by 16.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Novo Nordisk A/S (1985–2025)
The table below shows the annual total assets of Novo Nordisk A/S from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $542.90 Billion | +16.55% |
| 2024-12-31 | $465.80 Billion | +48.11% |
| 2023-12-31 | $314.49 Billion | +30.35% |
| 2022-12-31 | $241.26 Billion | +24.03% |
| 2021-12-31 | $194.51 Billion | +716.50% |
| 2020-12-31 | $23.82 Billion | +26.25% |
| 2019-12-31 | $18.87 Billion | -82.97% |
| 2018-12-31 | $110.77 Billion | +8.22% |
| 2017-12-31 | $102.36 Billion | +4.94% |
| 2016-12-31 | $97.54 Billion | +6.25% |
| 2015-12-31 | $91.80 Billion | +19.12% |
| 2014-12-31 | $77.06 Billion | +9.56% |
| 2013-12-31 | $70.34 Billion | +7.11% |
| 2012-12-31 | $65.67 Billion | +1.50% |
| 2011-12-31 | $64.70 Billion | +5.37% |
| 2010-12-31 | $61.40 Billion | +12.17% |
| 2009-12-31 | $54.74 Billion | +7.92% |
| 2008-12-31 | $50.73 Billion | +6.13% |
| 2007-12-31 | $47.80 Billion | +6.93% |
| 2006-12-31 | $44.70 Billion | +6.68% |
| 2005-12-31 | $41.90 Billion | +11.14% |
| 2004-12-31 | $37.70 Billion | +9.30% |
| 2003-12-31 | $34.49 Billion | +9.65% |
| 2002-12-31 | $31.45 Billion | +9.10% |
| 2001-12-31 | $28.83 Billion | +17.19% |
| 2000-12-31 | $24.60 Billion | -20.75% |
| 1999-12-31 | $31.04 Billion | +13.54% |
| 1998-12-31 | $27.34 Billion | +6.44% |
| 1997-12-31 | $25.69 Billion | +22.04% |
| 1996-12-31 | $21.05 Billion | +4.47% |
| 1995-12-31 | $20.15 Billion | -4.66% |
| 1994-12-31 | $21.13 Billion | +9.82% |
| 1993-12-31 | $19.24 Billion | +14.69% |
| 1992-12-31 | $16.78 Billion | +9.85% |
| 1991-12-31 | $15.27 Billion | +22.18% |
| 1990-12-31 | $12.50 Billion | +7.20% |
| 1989-12-31 | $11.66 Billion | +26.38% |
| 1988-12-31 | $9.23 Billion | +11.61% |
| 1987-12-31 | $8.27 Billion | +1.43% |
| 1986-12-31 | $8.15 Billion | +10.70% |
| 1985-12-31 | $7.36 Billion | -- |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more